A practical reference on reference standard: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-10. Anything still debated is marked as such rather than presented as settled.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
{\displaystyle {\frac {\partial }{\partial t}}\left(\nabla ^{2}\psi \right)+{\frac {\partial \psi }{\partial y}}{\frac {\partial }{\partial x}}\left(\nabla ^{2}\psi \right)-{\frac {\partial \psi }{\partial x}}{\frac {\partial }{\partial y}}\left(\nabla ^{2}\psi \right)=\nu \nabla ^{4}\psi }
On 7 December 2024, the Syrian opposition group known as the Southern Operations Room, in co-ordination with the Military Operations Command, led forces that entered the Rif Dimashq region of Syria from the south, and those forces then came within 20 kilometres (12 mi) of the capital Damascus. The Syrian Army withdrew from multiple points in the outskirts. Concurrently with the advance towards Damascus, opposition militia Tahrir al-Sham and the Turkish-backed Syrian National Army in the north launched an offensive into Homs, while the Syrian Free Army advanced into the capital from the southeast. By 8 December 2024, rebel forces entered the city's Barzeh neighborhood. According to official state reports in Russian mass media and media footage, President Bashar al-Assad left Damascus by air to Moscow, where he was granted asylum, sealing the fall of his regime.
== Research == Liposomal medicine research for cancer therapy has increased over the years as an alternative to conventional cancer treatment. There is an interest in liposomal medicine because it features targeted drug delivery while mitigating the damage to healthy cells and tissues. One of the combination products under liposome therapy that is being researched for cancer therapy applications is immunoliposome therapy. Other research areas in liposome combination therapy include photodynamic therapy, photothermal agents, radiotherapy, and gas therapy agents. A immunoliposome therapy clinical study that was completed was conducted by the Swiss Group for Clinical Cancer Research from 2006 to 2009. The study was a phase II clinical trial that looked at the combination of commercially sold Doxorubicin with bevacizumab, a monoclonal antibody that blocks tumor growth. The therapy was used to treat patients with locally recurrent or metastatic breast cancer. Out of the 43 patients, 16 had grade 3 palmar-plantar erythrodysesthesia, one had grade 3 mucositis, and one severe cardiotoxicity, according to the study. As a result, the combination therapy demonstrated higher than anticipated toxicity while only having modest therapeutic effect. These results concluded that, although immunoliposome therapy has promise, there is still more research needed before translating into commercial products.
Sources: en.wikipedia.org
=== Pharmacodynamics === Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and does not appreciably inhibit norepinephrine and dopamine reuptake at therapeutic doses. It does, however, delay the reuptake of serotonin, resulting in serotonin persisting longer when it is released. Large doses in rats have been shown to induce a significant increase in synaptic norepinephrine and dopamine. Thus, dopamine and norepinephrine may contribute to the antidepressant action of fluoxetine in humans at supratherapeutic doses (60–80 mg). This effect may be mediated by 5HT2C receptors, which are inhibited by higher concentrations of fluoxetine. Fluoxetine increases the concentration of circulating allopregnanolone, a potent GABAA receptor positive allosteric modulator, at concentrations that are inactive on serotonin reuptake. Norfluoxetine, a primary active metabolite of fluoxetine, produces a similar effect on allopregnanolone levels in the brains of mice. Additionally, both fluoxetine and norfluoxetine are such modulators themselves, actions which may be clinically relevant. In addition, fluoxetine has been found to act as an agonist of the σ1-receptor, with a potency greater than that of citalopram but less than that of fluvoxamine. However, the significance of this property is not fully clear. Fluoxetine also functions as a channel blocker of anoctamin 1, a calcium-activated chloride channel. A number of other ion channels, including nicotinic acetylcholine receptors and 5-HT3 receptors, are also known to be inhibited at similar concentrations.
A few small trials have found benefits in people with depression. A 2021 meta-analysis supports the usefulness of botox in unipolar depression, but finds significant heterogenity among the findings. The main hypothesis for its action is based on the facial feedback hypothesis. Another hypothesis involves a connection between the facial muscle and specific brain regions in animals, but additional evidence is required to support or disprove this theory.
The polymerization of one kind of monomer gives a homopolymer. Many polymers are copolymers, meaning that they are derived from two different monomers. In the case of condensation polymerizations, the ratio of comonomers is usually 1:1. For example, the formation of many nylons requires equal amounts of a dicarboxylic acid and diamine. In the case of addition polymerizations, the comonomer content is often only a few percent. For example, small amounts of 1-octene monomer are copolymerized with ethylene to give specialized polyethylene.
The French censor cut some violent scenes and made the director change the end of his movie which was seen as "too pessimistic". Léo Joannon's film Fort du Fou (Fort of the Mad) /Outpost in Indochina was released in 1963. Another film was The 317th Platoon (La 317ème Section) was released in 1964, it was directed by Indochina War (and siege of Dien Bien Phu) veteran Pierre Schoendoerffer. Schoendoerffer has since become a media specialist about the Indochina War and has focused his production on realistic war movies. He was cameraman for the army ("Cinematographic Service of the Armies", SCA) during his duty time; moreover, as he had covered the Vietnam War he released The Anderson Platoon, which won the Academy Award for Documentary Feature. Graham Greene's novel The Quiet American takes place during this war. In 2011, Vietnamese software developer Emobi Games released a first-person-shooter called 7554. Named after the date 07-05-54 (7 May 1954) which marks the end of the decisive Battle of Dien Bien Phu, it commemorates the First Indochina War from the Vietnamese point of view. The 2017 film by Olivier Lorelle, Ciel Rouge, starring Cyril Descours and Audrey Giacomini, is set during the early part of the First Indochina War.
Sources: en.wikipedia.org
The observation of such magnetic resonance frequencies of the nuclei present in a molecule makes it possible to determine essential chemical and structural information about the molecule. The improvements of the NMR method benefited from the development of electromagnetic technology and advanced electronics and their introduction into civilian use. Originally as a research tool it was limited primarily to dynamic nuclear polarization, by the work of Anatole Abragam and Albert Overhauser, and to condensed matter physics, where it produced one of the first demonstrations of the validity of the BCS theory of superconductivity by the observation by Charles Slichter of the Hebel-Slichter effect. It soon showed its potential in organic chemistry, where NMR has become indispensable, and by the 1990s improvement in the sensitivity and resolution of NMR spectroscopy resulted in its broad use in analytical chemistry, biochemistry and materials science. In the 2020s zero- to ultralow-field nuclear magnetic resonance (ZULF NMR), a form of spectroscopy that provides abundant analytical results without the need for large magnetic fields, was developed. It is combined with a special technique that makes it possible to hyperpolarize atomic nuclei.
=== Binding === DCBQ is an electrophilic compound, so it can bind in the human body to multiple nucleophilic compounds. DCBQ can, for instance, react with GSH, substituting the Cl groups for the GS group. DCBQ is thus being dechlorinated and can undergo Michael addition with GSH, resulting in more glutathionylated products. The second Cl group can also be removed from the compound when reacting with another GSH molecule. DCBQ can also undergo redox reactions when reacting with an electron, forming radicals. These radicals can also react with GSH, forming more conjugation products. DCBQ can also react with amino acids. When DCBQ was brought in contact with amino acids, the DCBQ was quickly removed, suggesting that the DCBQ reacted with the amino acids. DCBQ binds to the DNA via H-bonds, a non-covalent interaction. Because of its hydrophobicity, DCBQ might be intercalated between nucleotides in a double-stranded DNA molecule [source]. This intercalation might lead to increased access to the nucleotides, possibly leading to even more oxidative damage in the DNA. Amino acids can also covalently bind to DCBQ. The amino acids undergo nucleophilic substitution with both DCBQ and DCBQ-OH, the product of DCBQ hydrolysis. Proteins can be bound by DCBQ covalently via cysteine or lysine residues. Catechins, which are naturally present in for instance green tea, can competitively bind to DCBQ, reducing the amount of proteins bound to DCBQ [16]. The proteins are covalently modified when bound to DCBQ, which might change the stability and alter the function of the protein.
==== PROSITE pattern notation ==== The PROSITE notation uses the IUPAC one-letter codes and conforms to the above description with the exception that a concatenation symbol, '-', is used between pattern elements, but it is often dropped between letters of the pattern alphabet. PROSITE allows the following pattern elements in addition to those described previously:
==== Creation of other synthetic psychedelics ==== The synthetic mescaline analogue 2,6-dibromomescaline was described by Arthur Heffter in 1901, although he is not known to have tested it and its psychedelic effects weren't reported until much later. The psychedelic effects of 3,4-methylenedioxyamphetamine (MDA), a synthetic analogue of mescaline that had been derived from amphetamine in 1910, were discovered by American chemist and pharmacologist Gordon Alles in 1930, but weren't subsequently published until 1959. 3,4,5-Trimethoxyamphetamine (TMA), another synthetic mescaline analogue, was first described in 1947 and its psychedelic effects were described in 1955. 2,4,5-Trimethoxyphenethylamine (2C-O), a synthetic positional isomer of mescaline, was synthesized and claimed to be psychedelic similarly to mescaline in 1931, but later trials found it to be inactive. Various synthetic tryptamine psychedelics, such as diethyltryptamine (DET), 4-PO-DET (CEY-19), and 4-HO-DET (CZ-74), were developed in the late 1950s. In addition, the synthetic α-alkyltryptamine analogues α-methyltryptamine (AMT; Indopan) and α-ethyltryptamine (AET; Monase), which are psychedelics and/or entactogens, were marketed and clinically used at non-hallucinogenic doses as antidepressants in the early 1960s, but were quickly withdrawn due to physical toxicity. Numerous synthetic psychedelic tryptamines were known by the mid-1970s. Alexander Shulgin, an American chemist working at Dow Chemical Company, tried mescaline by 1960.
Red blood cell concentrates are produced either from whole blood or by apheresis. Production from whole blood is far more common than apheresis due to collection and production efficacy as well as economical purposes. When red blood cell concentrates are produced from whole blood, the whole blood is first separated through centrifugation (usually between 3000 to 5000 x g). The red blood cells are denser than plasma and the other present blood cells (platelets, white blood cells) and settle at the bottom of the blood bag. After centrifugation, the red blood cells are separated from the other components (the majority of the plasma, platelets and white blood cells) through the use of an extractor (also referred to as blood press). After extraction, an additive solution is usually added in a ratio of 1:1.5 to 1:2. The purpose of the additive solution is to maintain adequate viscosity, provide nutrients and ATP/GTP building blocks and reduce haemolysis generation throughout blood bank storage. Choice of additive solution has an impact on the red blood cell viability and, thereby, shelf life (expiry date) of the red blood cell concentrate. Usually, shelf life is limited to 4 to 6 weeks, provided that the red blood cell concentrates are stored in adequate conditions (2-6 °C). Commercial additive solutions are typically based on saline. They usually contain glucose, adenine, mannitol and, sometimes, phosphate and guanosine. The additive solution has no, or very little, buffering capacity, but buffering is provided by the red blood cells themselves.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.